Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials
Why the study?
Diverse neurological endpoint definitions and ascertainment methods in cardiovascular clinical trials have created uncertainty regarding neurological risks and led to inconsistent evaluation of preventive therapies.
Design
International consensus document
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“As even the smallest damage to particular parts of the brain can impact a patient's memory and day-to-day ability to function, my colleagues and I have grown increasingly concerned that safety evaluations of the newer cardiovascular procedures only evaluate the extreme life-threatening forms of brain damage. This paper outlines the need to use and report more modern and sensitive measures to evaluate brain injury related to cardiac procedures.”
“Until now, many studies evaluating the safety of TAVI and other cardiovascular procedures only recorded the most devastating strokes, which meant that doctors—and their patients—were unaware of the full risk potential. We hope this paper will cause researchers to report their findings in a more comprehensive and consistent way so that clinicians can properly interpret the results to provide the best care to patients.”
“The current stroke definitions used in cardiovascular trials focus on the most extreme, devastating strokes, which are only one component of a spectrum of brain injury that is relevant to patients with cardiovascular disease.”
Implication
Clinicians should note risks of covert brain injury beyond overt stroke in TAVI; leaves open cognitive impact pending standardized trial adoption.
Key Points
- Establish an international consensus on the definition, classification, and assessment of neurological endpoints in clinical trials evaluating cardiovascular procedures.
- Convened an international collaboration through the Neurologic Academic Research Consortium.
- Assessed existing variability in neurological endpoint definitions and ascertainment techniques across surgical, catheter-based, and pharmacological cardiovascular trials.
- Defined standardized, harmonized criteria to capture the full spectrum of neurovascular injury and its clinical consequences.
- Provided unified ascertainment methods to systematically evaluate procedure-related neurological risks and the comparative effectiveness of neuroprotective therapies.
Structured PICO
P
Population
Patients in cardiovascular clinical trials evaluating surgical, catheter-based procedures, and adjunctive pharmacology
I
Intervention
Standardized definitions, classification, and assessment of neurological endpoints proposed by the Neurologic Academic Research Consortium
The proposed standardized neurological endpoints aim to improve the consistency and accuracy of evaluating neurological risks and preventive therapies in cardiovascular clinical trials.
Cite This Study
Lansky et al. (2017) studied this question.